These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 37109539)

  • 1. Androgen-Induced Cardiovascular Risk in Polycystic Ovary Syndrome: The Role of T Lymphocytes.
    Moulana M
    Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features.
    Daan NM; Jaspers L; Koster MP; Broekmans FJ; de Rijke YB; Franco OH; Laven JS; Kavousi M; Fauser BC
    Hum Reprod; 2015 Oct; 30(10):2376-86. PubMed ID: 26269538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.
    Wild RA; Carmina E; Diamanti-Kandarakis E; Dokras A; Escobar-Morreale HF; Futterweit W; Lobo R; Norman RJ; Talbott E; Dumesic DA
    J Clin Endocrinol Metab; 2010 May; 95(5):2038-49. PubMed ID: 20375205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of NT-probnp levels and cardiovascular disease risk factors in lean women with polycystic ovary syndrome.
    Karadağ C; Yoldemir T
    J Obstet Gynaecol; 2019 Nov; 39(8):1154-1159. PubMed ID: 31215274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications.
    Sirmans SM; Weidman-Evans E; Everton V; Thompson D
    Ann Pharmacother; 2012 Mar; 46(3):403-18. PubMed ID: 22388330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of markers of endotoxemia in women with polycystic ovary syndrome.
    Banaszewska B; Siakowska M; Chudzicka-Strugala I; Chang RJ; Pawelczyk L; Zwozdziak B; Spaczynski R; Duleba AJ
    Hum Reprod; 2020 Oct; 35(10):2303-2311. PubMed ID: 32869098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular disease risk in offspring of polycystic ovary syndrome.
    Shawky NM
    Front Endocrinol (Lausanne); 2022; 13():977819. PubMed ID: 36531474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Perforin and Granzyme-B Levels with Hyperandrogenism in Polycystic Ovary Syndrome: A Case-Control Study.
    Zarei E; Mohajery H; Aliakbari F; Zadeh FM; Veghari G; Mansourian A
    Pak J Biol Sci; 2019 Jan; 22(8):393-399. PubMed ID: 31930827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular health and menopause in aging women with polycystic ovary syndrome.
    Helvaci N; Yildiz BO
    Expert Rev Endocrinol Metab; 2020 Jan; 15(1):29-39. PubMed ID: 31990594
    [No Abstract]   [Full Text] [Related]  

  • 12. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome.
    Barrea L; Marzullo P; Muscogiuri G; Di Somma C; Scacchi M; Orio F; Aimaretti G; Colao A; Savastano S
    Nutr Res Rev; 2018 Dec; 31(2):291-301. PubMed ID: 30033891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgens drive microvascular endothelial dysfunction in women with polycystic ovary syndrome: role of the endothelin B receptor.
    Usselman CW; Yarovinsky TO; Steele FE; Leone CA; Taylor HS; Bender JR; Stachenfeld NS
    J Physiol; 2019 Jun; 597(11):2853-2865. PubMed ID: 30847930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Low Grade Inflammation in Pathogenesis of PCOS.
    Rudnicka E; Suchta K; Grymowicz M; Calik-Ksepka A; Smolarczyk K; Duszewska AM; Smolarczyk R; Meczekalski B
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33917519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome.
    Glintborg D; Rubin KH; Nybo M; Abrahamsen B; Andersen M
    Cardiovasc Diabetol; 2018 Mar; 17(1):37. PubMed ID: 29519249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Risk in Postmenopausal Women with Polycystic Ovary Syndrome.
    Armeni E; Lambrinoudaki I
    Curr Vasc Pharmacol; 2019; 17(6):579-590. PubMed ID: 30156159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome.
    Meun C; Gunning MN; Louwers YV; Peters H; Roos-Hesselink J; Roeters van Lennep J; Rueda Ochoa OL; Appelman Y; Lambalk N; Boersma E; Kavousi M; Fauser BC; Laven JS;
    Clin Endocrinol (Oxf); 2020 Feb; 92(2):150-158. PubMed ID: 31638273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women.
    Yousuf SD; Ganie MA; Urwat U; Andrabi SM; Zargar MA; Dar MA; Manzoor-Ul-Rehman M; Mudassar S; Rashid F
    BMC Womens Health; 2023 Feb; 23(1):68. PubMed ID: 36793022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome.
    Sung YA; Oh JY; Chung H; Lee H
    Fertil Steril; 2014 Mar; 101(3):840-5. PubMed ID: 24424368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycystic ovary syndrome and aging: Health implications after menopause.
    Helvaci N; Yildiz BO
    Maturitas; 2020 Sep; 139():12-19. PubMed ID: 32747035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.